Investigating the Connection Between Endometriosis and Cancer

At the University of Northampton, researchers are examining the biochemical link between endometriosis and ovarian cancer. Led by Danielle Jex, a senior lecturer in immunology, the study investigates whether chemical signals from endometriosis cells contribute to cancer cell survival and immune evasion.

Endometriosis affects about 10% of women of reproductive age globally. This condition occurs when tissue similar to the uterine lining grows outside the uterus, often leading to chronic pain and infertility. Ovarian cancer, the most lethal gynecological malignancy, has a five-year survival rate of around 49%, according to the World Health Organization. Understanding the relationship between these conditions could enhance therapies and refine early detection strategies.

"Endometriosis is still widely misunderstood and under-diagnosed, with many people waiting years for answers," said Jex. The average delay between symptom onset and diagnosis is about seven years, highlighting barriers in recognizing women’s health issues. Jex’s team focuses on how inflammatory processes in endometriosis may foster a tumor-friendly microenvironment.

Research has shown that women with endometriosis are 1.5 times more likely to develop ovarian cancer than those without, according to a 2018 meta-analysis in The Lancet Oncology. However, causation remains unclear, and much research lacks molecular insights—exactly what Jex’s study aims to address.

One investigation area is cytokines, proteins crucial for immune responses. Initial findings indicate that cytokine imbalances in endometriosis may inadvertently protect cancer cells from immune detection. Ongoing data collection could lead to significant treatment implications. Targeted therapies disrupting these signaling pathways might complement existing treatments, from surgery to chemotherapy.

This research is part of a broader effort to elevate women’s health issues in medical research. "Historically, endometriosis has been trivialized as simply ‘bad cramps,’ and ovarian cancer has been deemed too rare for substantial screening investment," said Dr. Lillian Harris, a gynecologic oncologist at King’s College Hospital in London. "When you start connecting dots, the case for more robust funding becomes hard to ignore."

Harris highlights advancements in diagnostic imaging, genetic profiling, and artificial intelligence as tools to enhance research synergies. A pilot program launched in 2022 by the UK’s National Health Service is using AI algorithms to screen for ovarian cancer risk factors in women with endometriosis symptoms. Early reports indicate a 15% increase in actionable referrals to specialists, though peer-reviewed validation is pending.

Despite scientific progress, barriers persist. Endometriosis lacks a non-invasive diagnostic test, relying on laparoscopic surgery for confirmation—a costly and inaccessible procedure for many. Similarly, the absence of a universal ovarian cancer screening test leaves high-risk individuals vulnerable.

"The intersection of these two conditions represents a dual crisis," said Jex, addressing both medical complexity and systemic biases that hinder progress in women’s health. She emphasized the need to raise public awareness. "We need to address the stigma and misinformation surrounding conditions like endometriosis. Delays in seeking care often stem from cultural taboos that discourage women from advocating for their symptoms."

The University of Northampton’s research is in early stages, with clinical trials not expected until at least 2028. However, findings could lead to collaborations with pharmaceutical companies and health agencies. "If we can demonstrate a clear mechanistic link, the next logical step would be to identify druggable targets," said Jex. "That could fundamentally change the treatment landscape for both conditions."

For patients like Maria Ferri, a 34-year-old from Milan diagnosed with both endometriosis and ovarian cancer in 2021, advances in understanding are urgent. "It’s frustrating to know how little doctors can tell you about why this is happening," Ferri said. "Even if I’m already in treatment, knowing more might help other women avoid what I’ve been through."

As research progresses, the critical question remains whether healthcare systems will adapt swiftly enough to integrate new findings into practice. From updating diagnostic guidelines to funding large-scale trials, the transition from academic theory to medical implementation often lags by a decade or more. The stakes remain high, and time is of the essence.